Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

LJLi JCJChunyan JiTZTaigang Zhu

Discussion

Loading...

Member takes

Overview

Multicenter retrospective analysis identifies FLT3 mutations as prognostic factors in AML, suggesting chemotherapy impacts outcomes.

Key Points

  • The study aims to identify prognostic factors for patients with newly diagnosed AML with FLT3 mutations.
  • Retrospective multicenter cohort study of AML patients with FLT3 mutations
  • Frontline therapy data collected from East China Leukemia Alliance
  • Comprehensive cytogenetic analysis and next-generation sequencing employed
  • FLT3 mutations identified in a significant subset of patients with AML
  • Median overall survival was 34.0 months; complete remission achieved in 79.2% of cases
  • Combination therapy of hypomethylating agents and venetoclax showed potential benefits compared to chemotherapy alone

Cite This Study

J et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da11https://doi.org/10.1182/blood-2025-5182
View Full Paper
Ask AI
Bookmark
Share